16 Apr Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma
Posted at 11:30h in Blogs 0 Comments
Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months was 93%. At 2 years, 69% of patients could discontinue ibrutinib because of undetectable MRD. (Ref: Giné E et al. J Clin Oncol. 2022)
Sorry, the comment form is closed at this time.